Clinical improvement induced by rituximab in two cases of type II mixed cryoglobulinaemia syndrome unresponsive to conventional treatments

Blood Transfusion

Volumn 8, Issue 3, 2010, Pages 196-198

  Cabibbo, Sergio ^a   Antolino, Agostino ^a   Garozzo, Giovanni ^a   Manenti, Giovanna O ^a   Bonomo, Pietro ^a  

^a Azienda Ospedaliera Civile Maria Paterno Arezzo   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PREDNISONE; RITUXIMAB;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CASE REPORT; CLINICAL FEATURE; CRYOGLOBULINEMIA; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INFECTION; MALE; POLYMERASE CHAIN REACTION; RELAPSE; SYMPTOM; TREATMENT RESPONSE;

AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CRYOGLOBULINEMIA; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 77954408757     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2010.0093-09     Document Type: Article

References (6)

1. De Vita S, Quartuccio L, Fabris M. Rituximab in mixed cryoglobulinemia: increased experience and perspectives. Dig Liver Dis 2007; 39(Suppl.1): S122-8.
2. Zaja F, De Vita S, Mazzero C, et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003; 101: 3827-34.
3. Cacoub P, Delluc A, Saadoun D, et al. Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand ?. Ann Rheum Dis 2008; 67: 283-7.
4. Saandoun D, Delluc A, Piette JC, et al. Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitis. Curr Opin Rheumatol 2008; 20: 23-8. (Pubitemid 351339428)
5. Fabrizi F, Lunghi G, Messa P, et al. Therapy of hepatitis C virus-associated glomerulonephritis: current approaches. J Nephrol 2008; 21: 813-25
6. Ahmed MS, Wong CF. Should rituximab be the rescue therapy for refractory mixed cryoglobulinemia associated with hepatitis C? J Nephrol 2007; 20: 350-6.